卡非佐米联合美法仑预处理用于多发性骨髓瘤自体干细胞移植的1/2期研究(CARAMEL)
这项1/2期研究在≤2线治疗的多发性骨髓瘤患者中,将卡非佐米加入大剂量美法仑预处理后进行自体干细胞移植。1期剂量递增组14例,2期组35例,最大耐受剂量为56 mg/m2。全队列移植后1年≥完全缓解率为22%,≥非常好的部分缓解率从移植前41%升至移植后1年77%。
要点
- 卡非佐米联合美法仑预处理的最高测试剂量56 mg/m2为最大耐受剂量。
- 全队列移植后1年≥完全缓解率为22%,最大耐受剂量组亦为22%。
- ≥非常好的部分缓解率从移植前41%提升至移植后1年77%。
核心结论
- 卡非佐米加入美法仑预处理是安全的,并使自体干细胞移植后获得深度缓解。
研究设计与样本
- 1/2期研究,1期剂量递增组纳入14例,2期组纳入35例。
- 纳入接受≤2线既往治疗的多发性骨髓瘤患者,在自体干细胞移植前接受卡非佐米联合大剂量美法仑预处理。
- 卡非佐米在移植前第-6、-5、-2、-1天按27、36、45、56 mg/m2递增给药,所有患者在第-4、-3天接受美法仑100 mg/m2。
- 1期主要终点为确定最大耐受剂量,2期主要终点为移植后1年完全缓解(≥CR)率。
主要发现
- 最高测试剂量56 mg/m2为最大耐受剂量。
- 从诊断至入组的中位时间为5.8个月(范围3.4-88.4个月),16%的患者在移植前已获得≥CR。
- 全队列移植后1年内最佳缓解≥CR率为22%,最大耐受剂量组为22%。
- ≥非常好的部分缓解率从移植前41%提升至移植后1年77%。
- 1例患者发生3级肾脏不良事件,经支持治疗后肾功能恢复至基线;3-4级心血管毒性发生率为16%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this phase 1/2 study, carfilzomib was added to high-dose melphalan conditioning prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma that had been treated with ≤2 prior lines of therapy. Carfilzomib was escalated at doses of 27, 36, 45, and 56 mg/m2 on days -6, -5, -2, and -1 before ASCT in the phase 1 component of the study. In addition, all the patients received melphalan 100 mg/m2 on days -4 and -3. The primary endpoint of the phase 1 component was to identify the maximum tolerated dose, and the primary endpoint of the phase 2 component was the rates of complete response (≥CR) at 1 year after ASCT. The phase 1 dose escalation cohort included 14 patients, and 35 patients were included in the phase 2 cohort. The maximum tested dose was 56 mg/m2 (MTD). The median time from diagnosis to study enrollment was 5.8 (range 3.4-88.4) months, and 16% of patients had obtained a ≥CR prior to ASCT. The best response within 1 year after ASCT was a ≥ CR rate in 22% for the entire cohort, and 22% for patients treated at the MTD. The ≥VGPR rates improved from 41% before ASCT to 77% by 1 year after ASCT. One patient had a grade 3 renal adverse event, and renal function returned to baseline with supportive care. The rate of grade 3-4 cardiovascular toxicity was 16%. The addition of carfilzomib to melphalan conditioning was safe and resulted in deep responses after ASCT.
引用
- Visram A, Hayman SR, Dispenzieri A, et al. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Am J Hematol. 2023. PMID: 37334773. doi:10.1002/ajh.26990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。